

TURNING POINT BRANDS DIRECTOR OF FDA SCIENCE PRESENTS ON ABUSE LIABILITY OF NICOTINE AND TOBACCO PRODUCTS

NYSE **TPB**
\$31.62 ▼ \$-0.17
08/05/2020 04:00 PM EDT
Price is delayed by 15 mins

October 07, 2019

LOUISVILLE, Ky.--(BUSINESS WIRE)-- Dr. Sarah E. Evans, Director of FDA Science for Turning Point Brands, Inc. (NYSE: TPB), will present *A Review of Current Methodologies in Evaluating Abuse Liability of Nicotine and Tobacco Products in the United States Regulatory Environment* during the 2019 CORESTA Smoke Science & Product Technology Conference in Hamburg, Germany, on October 6, 2019. CORESTA hosts experts from around the globe with the aim to provide an authoritative source of publicly available, credible science and best practices related to tobacco and its derived products.

Dr. Evans will present findings to summarize current consensus on the best abuse liability assessment methodologies for nicotine and tobacco products. Currently, no testing standards exist in the U.S. regulatory context to determine the abuse liability of these products to aid in obtaining a marketing order from the FDA. Dr. Evans's presentation will provide key considerations concerning the importance of abuse liability assessments in a number of areas relevant to FDA premarket filings and will summarize regulatory requirements and challenges.

"Dr. Evans is a valuable asset not only to Turning Point Brands but to the ongoing conversation around how best to reasonably regulate the rapidly evolving tobacco and vapor products categories," said Larry Wexler, President and CEO of TPB. "We are honored to have Dr. Evans representing Turning Point's continued commitment to scientific advancement in these products at the CORESTA 2019 Joint Conference of the Smoke Science and Product Technology Study Groups."

Dr. Sarah Evans has over 20 years of experience working in the field of nicotine and tobacco. She spent seven years working for the U.S. Food and Drug Administration's Center for Tobacco Products as a Behavioral Pharmacologist where she won numerous FDA awards. Dr. Evans' experience also includes work at the National Cancer Institutes' Tobacco Control Research Branch, experimental research at Virginia Commonwealth University on potential reduced exposure products (PREPS), and tenure as the former Executive Director of the Society for Research on Nicotine and Tobacco (SRNT).

About Turning Point Brands, Inc.

Louisville, Kentucky-based Turning Point Brands, Inc. (NYSE:TPB) is a leading U.S. provider of Other Tobacco Products and alternative products. TPB, through its focus brands, Stoker's® in Smokeless products, Zig-Zag® in Smoking products and VaporBeast® and VaporFi® in NewGen products, generates solid cash flow which it uses to finance acquisitions, increase brand support and strengthen its capital structure. More information about the company is available at its corporate website, www.turningpointbrands.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20191007005235/en/>

ir@tpbi.com

Robert Lavan, CFO

(502) 774-9238

Source: Turning Point Brands, Inc.